In very recent studies, procaspase 3 has been associated with CRC disease progression and overall survival [31], in part because its fragmentation during inflammation or after cancer therapy increases the levels of caspase 3 active form, which leads to constitutive activation of iPLA2 [32]. This evidence concerns the gene PLA2G6 and cancer.